The prognosis of patients with breast cancers has improved: Five-year survival has been 21 about 90% in recent years(7) partially because the increased use of adjuvant therapies such as 22 chemo-and radiotherapy. Recent advance in radiotherapy techniques substantially reduces the 23 radiation exposure to hearts during radiotherapy of breast cancers, which reduces the incidence of 24 cardiovascular diseases caused by atherosclerosis. However, even a low level of radiation exposure 25 to the hearts during contemporary radiotherapy of breast cancers still provide a deleterious impact on 26 coronary microvasculature, which is associated with the increased risk of heart failure with preserved 27 ejection fraction (HFpEF) with the mean cardiac radiation dose(12). Thus, radiation-induced 28 cardiovascular disease, especially HFpEF, emerges as the most important competing mortality risk 29 for breast cancer survivors(1).
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The effects of cardiac radiation on left ventricular (LV) diastolic function remain to be 31 poorly characterized, so far. Although the previous studies demonstrated the link between cardiac 32 radiation exposure and subsequent microvascular rarefaction in both animal models and patients with 33 breast cancer, LV diastolic function has not been assessed (9, 14) . In this issue of the American 
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The current study also demonstrated that radiation exposure induces both slowed/incomplete 65 left ventricular relaxation and increased passive chamber stiffness through coronary microvascular 66 endothelial inflammation with rarefaction and fibrosis. However, the molecular and cellular 67 mechanistic insights remain to be addressed (Fig. 1) . The several questions arise as to whether the Even though we have to remember that cardiovascular risk may differ even among the individuals 95 receiving the same radiation dose depending on the preexisting age-and comorbidity-related 96 myocardial abnormalities, the current radiation exposure-related HFpEF model will provide us the 97 opportunity to reveal novel signaling cascades and therapeutic targets against HFpEF cause by not 98 only radiation-driven but also comorbidity-driven coronary microvascular endothelial inflammation. Figure 1 
